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Abstract
Leber Hereditary Optic Neuropathy (LHON) is an important cause of inherited mitochondrial blindness among young adults.
The majority of patients carry one of three mitochondrial DNA (mtDNA) point mutations: m.3460G.A, m.11778G.A and
m.14484T.C, all of which affect critical complex I subunits of the mitochondrial respiratory chain. LHON is characterised by
marked incomplete penetrance, clearly implying that the mtDNA mutation is insufficient on its own to trigger retinal
ganglion cell dysfunction and visual loss. In this case series of three affected patients harbouring the m.11778G.A
mutation, we provide evidence suggesting that raised intraocular pressure could be a risk factor triggering visual loss in at-
risk LHON carriers.
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Introduction
Leber Hereditary Optic Neuropathy (LHON) is a primary
mitochondrial DNA (mtDNA) disorder that classically presents in
the second and third decades of life with bilateral, subacute, severe
visual loss [1,2]. The visual prognosis is poor and the majority of
patients remain significantly visually impaired. About 90% of
patients will harbour one of three common causative mtDNA
mutations: m.3460G.A, m.11778G.A, and m.14484T.C [3].
An intriguing, and as yet unexplained, aspect of LHON is the
marked incomplete penetrance observed in this mitochondrial
disorder, with only ,50% of male carriers and ,10% of female
carriers experiencing visual loss during their lifetime [1,2]. The
mtDNA mutation is clearly insufficient on its own and a number of
secondary nuclear genetic factors and environmental triggers have
been implicated to account for this disparity. In a recent large
study of 125 independent LHON families, smoking was strongly
associated with an increased risk of visual loss and a convincing
biological trend was observed when comparing light and heavy
smokers [4]. There are also a number of published cases reports
where disease conversion seemed to be temporally related to
insults such as head trauma [5–7], occupational inhalation of
chemical toxins [8], or secondary to iatrogenic exposure to
antituberculous or antiretroviral drugs [9–11]. Although these
causal links are difficult to prove unequivocally, the identification
of modifiable environmental triggers is especially important given
the current paucity of effective treatment strategies in LHON
[1,2]. In this case series of three affected patients carrying the
m.11778G.A mtDNA mutation, we provide evidence suggesting
that raised intraocular pressure could be an exacerbating risk
factor precipitating retinal ganglion cell (RGC) dysfunction and
the onset of visual loss in susceptible LHON carriers.
Report of Cases
Case 1
A 63-year-old white man presented with sudden-onset, painless
visual loss in his right eye down to 6/60 (Table 1). Except for a
longstanding, divergent, amblyopic left eye (6/18), there was no
other significant past medical history. There was no family history
of early-onset visual loss. He was a long-term smoker with a daily
consumption of 10–15 cigars. At initial presentation, the
intraocular pressure was found to be markedly elevated in the
right eye (43 mmHg), but within the normal range in the left eye
(14 mmHg). The cornea was clear and gonioscopy showed wide-
open drainage angles. There was a right relative afferent pupillary
defect and a marked reduction in colour vision in the right eye.
Asymmetric cupping of the right optic disc was noted on fundus
examination (Figure 1). Fluorescein angiography was normal
with no evidence of optic disc leakage or vasculitis. The patient
was started on ocular anti-hypertensive treatment, but despite
adequate intraocular pressure control being achieved, visual acuity
in the right eye deteriorated further to count fingers over a one-
month period. The patient was subsequently referred to the neuro-
ophthalmology service and he was extensively investigated.
Magnetic resonance imaging (MRI) of the brain and orbit was
normal with no enhancement of the anterior visual pathways
noted with gadolinium contrast. Rather surprisingly, molecular
genetic testing eventually revealed the presence of a homoplasmic
m.11778G.A LHON mutation as the cause of this patient’s
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atypical, unilateral optic neuropathy. The patient’s left eye has
remained uninvolved over a four-year follow-up period.
Case 2
A 72-year-old white man had been under regular ophthalmo-
logical review for bilateral ocular hypertension (Table 1). He was
a non-smoker and there was no significant past medical or family
history. Satisfactory intraocular pressure control proved difficult to
achieve and glaucomatous progression in the left eye, with
intraocular pressures of 26 mmHg in both eyes, was documented
two months prior to LHON disease onset (Figure 2). At the time
of disease conversion, the patient became aware of painless visual
loss in his right eye over a two-week period. His best-corrected
visual acuities were 6/60 in the right eye and 6/9 in the left eye
when he first presented to the emergency department. Visual
deterioration in the left eye started two months later and at the
visual nadir, the patient could only perceive hand movements
bilaterally. Despite normal inflammatory markers and a low index
of suspicion for giant cell arteritis, the patient was started on oral
prednisolone (60 milligrams, once a day). No treatment effect was
observed and the steroid dose was rapidly tapered off. The patient
was admitted under the neuro-ophthalmology team for further
investigation. Neuroimaging was unremarkable and a lumbar
puncture showed normal cerebrospinal fluid constituents. LHON
was considered in the differential diagnosis and this was confirmed
by the identification of a homoplasmic m.11778G.A LHON
mutation.
Case 3
A 58-year-old white man was being managed by the glaucoma
team for right-sided advanced glaucoma and left-sided ocular
hypertension (Table 1). The right optic disc was already deeply
excavated when the diagnosis of primary open angle glaucoma
was first made. He was a non-smoker and there was no significant
past medical or family history. One year after raised intraocular
pressures were first recorded, the patient reported painless visual
loss in his right eye over a one-month period down to 3/60
(Figure 3). A peripapillary haemorrhage was present at the
superotemporal disc margin and the rapid visual deterioration was
ascribed to end-stage glaucomatous damage in an already severely
compromised optic nerve. Nine months later, the patient
experienced rapid visual loss in his left eye with an expanding
dense central scotoma. At the nadir, the patient’s best-corrected
visual acuities were 3/60 bilaterally. MRI of the brain and orbit
with gadolinium contrast enhancement was normal. A neuro-
ophthalmological second opinion was sought and the patient was
found to harbour a homoplasmic m.11778G.A LHON mutation
during his investigative work-up. He self-initiated treatment with
idebenone (300 milligrams, three times a day) shortly after the
molecular diagnosis was made (Table 1). The visual acuity in his
right eye gradually improved to 6/9 over the following two-year
period and the patient has opted to remain on long-term
idebenone treatment. This study had the relevant institutional
ethical approval (County Durham & Tees Valley 1 Research
Ethics Committee, 08/H0905/106) and it was carried out in
compliance with the Declaration of Helsinki. Participants provided
their written consent for genetic testing and participation into this
study.
Discussion
Irrespective of sex and mutational status, the majority of LHON
carriers lose vision before the age of 50 years and this
epidemiological observation has been confirmed in different
geographical populations [1,2]. The three patients in this report
therefore represent relatively late-onset cases, raising some rather
intriguing questions as to the possible triggers for visual loss in
these otherwise healthy m.11778G.A mutation carriers. Unilat-
eral optic neuropathy has been described only rarely in LHON
[6,12–15], and it is tempting to draw a possible causal link
between the atypical, unilateral clinical course in Patient 1 and the
finding of a markedly raised intraocular pressure in the affected
right eye. Over a four-year follow-up period, the left eye has
remained uninvolved with normal intraocular pressures without
treatment. Patients 2 and 3 were being actively managed for
bilateral raised intraocular pressures before the onset of visual loss
from LHON. For Patient 2, intraocular pressure control had been
suboptimal and glaucomatous cupping of the left optic disc was
documented two months before LHON disease conversion.
Patient 3 had advanced optic disc cupping and significant field
loss in his right eye when he was first diagnosed with primary open
angle glaucoma. The rapid visual deterioration that developed a
year later in the same eye was thought to be due to end-stage
Figure 1. Optic disc appearance and visual fields of Patient 1. (A) Right optic disc cupping (arrow) was noted when the patient first presented
with visual loss in the right eye. The left optic disc was normal. HumphreyTM visual field perimetry was carried out using the 24-2 SITA-FAST protocol.
The right visual field showed a caecocentral scotoma with superior and inferior nasal step defects, in keeping with glaucomatous optic nerve damage
prior to LHON disease onset (Mean deviation in September 2008: LE =22.48 dB, RE =222.06 dB). (B) Progression of right optic disc cupping with
pallor of the remaining neuroretinal rim. The left optic disc remained normal. A dense field defect was present in the right eye (Mean deviation in
August 2012: LE =22.78 dB, RE =229.25 dB). The changes in peripapillary retinal nerve fibre layer thickness over that period of time have been
provided in Figure S1.
doi:10.1371/journal.pone.0063446.g001
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central RGC loss, before involvement of the fellow eye raised the
suspicion of an alternative disease process. In all three LHON
patients, disease conversion therefore occurred on the background
of raised intraocular pressure, ongoing glaucomatous optic nerve
damage, or both. LHON is a complex multifactorial disease with
the primary causative mtDNA mutations being insufficient on
their own to precipitate visual loss. We therefore cannot exclude
the possibility that other secondary genetic and environmental risk
modifiers could have played contributory roles in the atypical
presentations of our three LHON cases, in addition to raised
intraocular pressure.
LHON patients invariably remain with the legal requirement
for blind registration as significant visual recovery is rare in this
mitochondrial disorder [16]. If it does occur, the improvement in
visual function is frequently modest with clearing islands of vision
developing slowly within the central scotoma (fenestrations)
typically in the first year after disease onset [1,2]. This pattern
of visual recovery is much more likely among young carriers
affected before the age of 20 years and with the m.14484T.C
mutation, which carries the best prognosis compared with the
other two primary LHON mutations [1,2]. The significant
improvement in central visual acuity observed in the right eye of
Patient 3 is therefore unusual, especially in the context of the
m.11778G.A mutation. Although no visual recovery occurred in
the left eye, the natural history could have been positively
influenced by the initiation of idebenone treatment, which has
shown promise as a possible neuroprotective agent in a recently
completed randomised placebo-controlled trial [17].
How could raised intraocular pressure be linked with an increased risk of
visual loss in LHON? RGC loss in this mitochondrial optic
neuropathy is ultimately the consequence of an underlying, self-
perpetuating bioenergetic deficit [18]. Raised intraocular pressure
could exacerbate the precarious homeostatic state prevailing in
RGCs carrying a pathogenic LHON mutation by further
impeding axoplasmic flow or by impairing the vascular supply at
the optic nerve head and the critical transition region spanning the
lamina cribosa. The parvocellular RGCs within the papilloma-
cular bundle have relatively small cross-sectional areas compared
with the larger magnocellular RGC population [19,20]. This
anatomical factor is likely to impose additional physical constraints
Figure 2. Optic disc appearance and visual fields of Patient 2. (A) Inferotemporal notching of the left optic disc was present at LHON disease
onset (arrow). The patient was unable to perform HumphreyTM visual field perimetry reliably. Goldmann visual fields showed a steep-sided
caecocentral scotoma in the right eye and a central scotoma in the left eye. (B) Advanced bilateral optic disc cupping with pallor of the remaining
neuroretinal rim. Although visual field assessment became increasingly difficult as the patient’s visual acuities deteriorated to count fingers in both
eyes, gradual peripheral field constriction was noted during the course of his follow-up visits. The changes in peripapillary retinal nerve fibre layer
thickness over that period of time have been provided in Figure S2.
doi:10.1371/journal.pone.0063446.g002
Figure 3. Optic disc appearance and visual fields of Patient 3. (A) Advanced cupping of the right disc with a small peripapillary haemorrhage
still persisting at the superotemporal disc margin (arrow). The patient had been aware of visual deterioration in the right eye since April 2007. Visual
loss started in the left eye in January 2008. (B) Advanced bilateral optic disc cupping with pallor of the remaining neuroretinal rim. The right panel
shows the progression of the visual field defects in both eyes at three different time points: (i) after the onset of visual loss in the right eye (Mean
deviation in December 2007: LE =21.05 dB, RE =225.10 dB); (ii) following disease onset in the fellow eye (Mean deviation in April 2008: LE =29.03
dB, RE =222.97 dB); and (iii) at the patient’s last follow-up visit (Mean deviation in August 2012: LE =217.03 dB, RE =227.40 dB). The changes in
peripapillary retinal nerve fibre layer thickness over that period of time have been provided in Figure S3.
doi:10.1371/journal.pone.0063446.g003
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to axoplasmic flow under pathological conditions, such as raised
intraocular pressure, particularly in the highly energy-dependent,
unmyelinated segment of the optic nerve. There is also mounting
evidence that mitochondrial dysfunction is a key element in the
pathophysiology of glaucomatous optic neuropathy [21–23].
Raised intraocular pressure has been shown to induce fragmen-
tation of the mitochondrial network within RGC axons, which
further compromises the efficiency of the mitochondrial respira-
tory chain and leads to the release of pro-apoptotic cytochrome c
molecules [24,25].
Could the postulated link between raised intraocular pressure and visual loss
in LHON be a chance association? We have estimated the odds of a
male LHON carrier losing vision beyond the age of 50 years and
also having elevated intraocular pressures over 30 mmHg at 1 in
33.8 million (Table 2). The affected LHON patients in this case
series all originate from the North of England, which encompasses
a catchment population of about three million individuals. The
identification of three such atypical cases in this defined
geographical region is therefore more than what would be
expected by chance alone. Interestingly, Nucci and colleagues have
recently described a 53-year-old woman with pre-existing primary
open angle glaucoma who developed bilateral sequential visual loss
five years after she was first diagnosed [26]. Similar to our own
case series, the patient had a number of unusual features that
initially confounded the underlying reason for her dramatic visual
deterioration; with a relatively late age of onset, no obvious
environmental triggers, and the absence of a maternal family
history of blindness. In addition, LHON is marked by a marked
sex bias with female carriers having a significantly lower risk of
disease conversion compared with male carriers. Although the case
report by Nucci and colleagues and our point estimates (Table 2)
both support a plausible pathological link, our hypothesis that
raised intraocular pressure could precipitate disease conversion in
LHON needs to be substantiated further and the recent
availability of in vivo disease models provides tractable experimen-
tal means of verifying this [27,28].
Various treatment algorithms have been proposed for the
management of ocular hypertension and primary open angle
glaucoma, including the target intraocular pressure that needs be
achieved [29–31]. Until further evidence becomes available, it
seems reasonable to set a lower threshold for initiating treatment
for LHON carriers given the possible deleterious consequences of
raised intraocular pressure on mitochondrial function and RGC
survival.
Supporting Information
Figure S1 Changes in peripapillary retinal nerve fibre
layer thickness for Patient 1. (A) April 2009: average
thickness OD=47.15 mm, OS=91.12 mm; (B) August 2012:
average thickness OD=59 mm, OS=89 mm. Measurements were
carried out either with the Fast RNFL (3.4) acquisition protocol on
a time-domain Stratus OCTTM (Carl Zeiss Meditec, Dublin, CA),
or the high-resolution spectral-domain CirrusTM (Carl Zeiss
Meditec, Dublin, CA).
(TIF)
Figure S2 Changes in peripapillary retinal nerve fibre
layer thickness for Patient 2. (A) April 2010: average
thickness OD=84.86 mm, OS=76.53 mm; (B) August 2012:
average thickness OD=57 mm, OS=69 mm.
(TIF)
Figure S3 Changes in peripapillary retinal nerve fibre
layer thickness for Patient 3. (A) April 2008: average
thickness OD=61.47 mm, OS=97.42 mm; (B) August 2012:
average thickness OD=66 mm, OS=73 mm.
(TIF)
Author Contributions
Conceived and designed the experiments: AT PGG PYWM. Performed
the experiments: AT PGG GH PFC PYWM. Analyzed the data: AT PGG
GH PFC PYWM. Wrote the paper: AT PYWM.
References
1. Yu-Wai-Man P, Griffiths PG, Chinnery PF (2011) Mitochondrial optic
neuropathies - Disease mechanisms and therapeutic strategies. Prog Retin Eye
Res 30: 81–114.
2. Fraser JA, Biousse V, Newman NJ (2010) The Neuro-ophthalmology of
Mitochondrial Disease. Surv Ophthalmol 55: 299–334.
3. Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, BronteStewart J, et al.
(1996) Primary pathogenic mtDNA mutations in multigeneration pedigrees with
Leber hereditary optic neuropathy. Am J Hum Genet 59: 481–485.
4. Kirkman MA, Yu-Wai-Man P, Korsten A, Leonhardt M, Dimitriadis K, et al.
(2009) Gene-environment interactions in Leber hereditary optic neuropathy.
Brain 132: 2317–2326.
5. Redmill B, Mutamba A, Tandon M (2001) Leber’s hereditary optic neuropathy
following trauma. Eye 15: 544–547.
6. Nagai A, Nakamura M, Kusuhara S, Kanamori A, Negi A (2005) Unilateral
manifestation of Leber’s hereditary optic neuropathy after blunt ocular.
Jpn J Ophthalmol 49: 65–67.
7. Edwards TL, Buttery RG, Mackey DA (2007) Is second eye involvement in
Leber’s hereditary optic neuropathy due to retro-chiasmal spread of apoptosis?
Neuro-Ophthalmology 31: 87–94.
8. Carelli V, Franceschini F, Venturi S, Barboni P, Savini G, et al. (2007) Grand
rounds: Could occupational exposure to n-hexane and other solvents precipitate
visual failure in Leber hereditary optic neuropathy? Environ Health Perspect
115: 113–115.
9. De Marinis M (2001) Optic neuropathy after treatment with antituberculous
drugs in a subject with Leber’s hereditary optic neuropathy mutation. J Neurol
248: 818–819.
10. Seo JH, Hwang J-M, Park SS (2010) Antituberculosis medication as a possible
epigenetic factor of Leber’s hereditary optic neuropathy. Clin Experiment
Ophthalmol 38: 363–366.
11. Mackey DA, Fingert JH, Luzhansky JZ, McCluskey PJ, Howell N, et al. (2003)
Leber’s hereditary optic neuropathy triggered by antiretroviral therapy for
human immunodeficiency virus. Eye 17: 312–317.
Table 2. Chance occurrence of raised intraocular pressure $30 mmHg in an affected LHON carrier.
Variable Odds Reference
a Carrier of one of three primary mtDNA LHON mutations (m.3460G.A, m.11778G.A, and m.14484T.C) 1 in 8,460 [32]
b Lifetime risk of visual loss for a male LHON carrier 1 in 2 [1,2]
c Disease conversion in a LHON carrier .50 years old 1 in 20 [32]
d Intraocular pressure $30 mmHg in an individual .50 years old 1 in 100 [33]
Chance co-occurrence of above variables (a6b6c6d) 1 in 33.8M
doi:10.1371/journal.pone.0063446.t002
Raised Intraocular Pressure in LHON
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e63446
12. Borruat FX, Sanders MD (1994) Atypical Leber Optic Neuropathy. Klin Monbl
Augenheilkd 204: 400–402.
13. Nikoskelainen EK, Huoponen K, Juvonen V, Lamminen T, Nummelin K, et al.
(1996) Ophthalmologic findings in leber hereditary optic neuropathy, with
special reference to mtDNA mutations. Ophthalmology 103: 504–514.
14. Dandekar SS, Graham EM, Plant GT (2002) Ladies with Leber’s hereditary
optic neuropathy: an atypical disease. Eur J Ophthalmol 12: 537–541.
15. Sugisaka E, Ohde H, Shinoda K, Mashima Y (2007) Woman with atypical
unilateral Leber’s hereditary optic neuropathy with visual improvement. Clin
Experiment Ophthalmol 35: 868–870.
16. Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, et al. (2009)
Quality of Life in Patients with Leber Hereditary Optic Neuropathy. Invest
Ophthalmol Vis Sci 50: 3112–3115.
17. Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, et al. (2011) A
randomized placebo-controlled trial of idebenone in Leber’s hereditary optic
neuropathy. Brain 134: 2677–2686.
18. Carelli V, La Morgia C, Valentino ML, Barboni P, Ross-Cisneros FN, et al.
(2009) Retinal ganglion cell neurodegeneration in mitochondrial inherited
disorders. Biochim Biophys Acta 1787: 518–528.
19. Sadun AA, Win PH, Ross-Cisneros FN, Walker SO, Carelli V (2000) Leber’s
hereditary optic neuropathy differentially affects smaller axons in the optic
nerve. Trans Am Ophthalmol Soc 98: 223–232; discussion 232–225.
20. Pan BX, Ross-Cisneros FN, Carelli V, Rue KS, Salomao SR, et al. (2012)
Mathematically Modeling the Involvement of Axons in Leber’s Hereditary
Optic Neuropathy. Invest Ophthalmol Vis Sci 53: 7608–7617.
21. Yu-Wai-Man P (2012) Mitochondrial Dysfunction in Glaucoma-Closing the
Loop. Invest Ophthalmol Vis Sci 53: 2438–2438.
22. Almasieh M, Wilson AM, Morquette B, Vargas JLC, Di Polo A (2012) The
molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res
31: 152–181.
23. Lascaratos G, Garway-Heath DF, Willoughby CE, Chau KY, Schapira AH
(2012) Mitochondrial dysfunction in glaucoma: understanding genetic influenc-
es. Mitochondrion 12: 202–212.
24. Ju WK, Kim KY, Lindsey JD, Angert M, Duong-Polk KX, et al. (2008)
Intraocular pressure elevation induces mitochondrial fission and triggers OPA1
release in glaucomatous optic nerve. Invest Ophthalmol Vis Sci 49: 4903–4911.
25. Ju WK, Kim KY, Lindsey JD, Angert M, Patel A, et al. (2009) Elevated
hydrostatic pressure triggers release of OPA1 and cytochrome c, and induces
apoptotic cell death in differentiated RGC-5 cells. Mol Vis 15: 120–134.
26. Nucci C, Martucci A, Mancino R, Cerulli L (2013) Glaucoma progression
associated with Leber’s hereditary optic neuropathy. Int ophthalmol 33: 75–77.
27. Yu H, Koilkonda RD, Chou T-H, Porciatti V, Ozdemir SS, et al. (2012) Gene
delivery to mitochondria by targeting modified adenoassociated virus suppresses
Leber’s hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A
109: E1238–E1247.
28. Lin CS, Sharpley MS, Fan W, Waymire KG, Sadun AA, et al. (2012) Mouse
mtDNA mutant model of Leber hereditary optic neuropathy. Proc Natl Acad
Sci U S A 109: 20065–20070.
29. Ou Y, Goldberg I, Migdal C, Lee PP (2011) A Critical Appraisal and
Comparison of the Quality and Recommendations of Glaucoma Clinical
Practice Guidelines. Ophthalmology 118: 1017–1023.
30. Burr J, Azuara-Blanco A, Avenell A, Tuulonen A (2012) Medical versus surgical
interventions for open angle glaucoma. Cochrane Database Syst Rev:
CD004399.
31. Burr JM, Botello-Pinzon P, Takwoingi Y, Hernandez R, Vazquez-Montes M, et
al. (2012) Surveillance for ocular hypertension: an evidence synthesis and
economic evaluation. Health Technol Assess 16: 1–271.
32. Man PY, Griffiths PG, Brown DT, Howell N, Turnbull DM, et al. (2003) The
epidemiology of Leber hereditary optic neuropathy in the North East of
England. Am J Hum Genet 72: 333–339.
33. Rahman ML, Bunce C, Healey PR, Mitchell P, Sham PC, et al. (2010)
Commingling analyses of central corneal thickness and adjusted intraocular
pressure in an older Australian population. Invest Ophthalmol Vis Sci 51: 2512–
2518.
Raised Intraocular Pressure in LHON
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e63446
